ATE265220T1 - Kostimulatorische blockade und gemischter chimerismus in allotransplantationen - Google Patents

Kostimulatorische blockade und gemischter chimerismus in allotransplantationen

Info

Publication number
ATE265220T1
ATE265220T1 AT99905798T AT99905798T ATE265220T1 AT E265220 T1 ATE265220 T1 AT E265220T1 AT 99905798 T AT99905798 T AT 99905798T AT 99905798 T AT99905798 T AT 99905798T AT E265220 T1 ATE265220 T1 AT E265220T1
Authority
AT
Austria
Prior art keywords
allotransplants
mixed chimerism
costimulatory blockade
blockade
costimulatory
Prior art date
Application number
AT99905798T
Other languages
English (en)
Inventor
Megan Sykes
Mohamed H Sayegh
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE265220T1 publication Critical patent/ATE265220T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Artificial Fish Reefs (AREA)
AT99905798T 1998-02-04 1999-02-04 Kostimulatorische blockade und gemischter chimerismus in allotransplantationen ATE265220T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7386498P 1998-02-04 1998-02-04
PCT/US1999/002542 WO1999039727A1 (en) 1998-02-04 1999-02-04 Costimulatory blockade and mixed chimerism in allotransplantation

Publications (1)

Publication Number Publication Date
ATE265220T1 true ATE265220T1 (de) 2004-05-15

Family

ID=22116269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905798T ATE265220T1 (de) 1998-02-04 1999-02-04 Kostimulatorische blockade und gemischter chimerismus in allotransplantationen

Country Status (9)

Country Link
US (3) US6280957B1 (de)
EP (2) EP1058555B1 (de)
JP (2) JP2002502824A (de)
AT (1) ATE265220T1 (de)
AU (2) AU748443B2 (de)
CA (2) CA2319448A1 (de)
DE (1) DE69916807T2 (de)
IL (2) IL137361A0 (de)
WO (2) WO1999039727A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723888T2 (de) * 1996-05-09 2004-05-27 The General Hospital Corp., Boston Gemischter Chimerismus und Toleranz
HUP0301208A2 (hu) * 1999-02-12 2003-08-28 Genetics Institute, Llc B7-molekulákkal reagáló humanizált immunglobulin és az ezekkel végzett kezelési eljárások
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2001000679A2 (en) * 1999-06-29 2001-01-04 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2392615A1 (en) * 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
WO2001068134A2 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
CA2436139A1 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
CA2486621A1 (en) * 2002-05-22 2003-12-04 The Cleveland Clinic Foundation Induction and maintenance of tolerance to composite tissue allografts
EP1658096A1 (de) * 2003-08-25 2006-05-24 PanGenetics B.V. Verfahren zur auslösung von immuntoleranz
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance
EP2338511A3 (de) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Verlängerung der Überlebungszeit eines Allografts durch Hemmung der Komplementsaktivität
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
KR101536239B1 (ko) 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
JP5722524B2 (ja) 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
US9527912B2 (en) * 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
JP6305443B2 (ja) 2013-02-26 2018-04-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 移植片の移植寛容のための組み合わされた臓器及び造血細胞
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
WO2019178106A1 (en) 2018-03-12 2019-09-19 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DE69331778T2 (de) 1992-01-08 2002-11-14 The General Hospital Corp., Boston Induzierte toleranz gegen transplantate
WO1994026289A1 (en) 1992-02-19 1994-11-24 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5869049A (en) 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
JPH10501815A (ja) 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
EP0892643B2 (de) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
DE69723888T2 (de) 1996-05-09 2004-05-27 The General Hospital Corp., Boston Gemischter Chimerismus und Toleranz
ATE283925T1 (de) 1996-07-23 2004-12-15 Tanox Pharma B V Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann

Also Published As

Publication number Publication date
AU2583999A (en) 1999-08-23
DE69916807D1 (de) 2004-06-03
DE69916807T2 (de) 2005-01-13
CA2319764A1 (en) 1999-08-12
US20020055122A1 (en) 2002-05-09
JP2002502824A (ja) 2002-01-29
AU746825B2 (en) 2002-05-02
US6514513B1 (en) 2003-02-04
WO1999039726A1 (en) 1999-08-12
AU748443B2 (en) 2002-06-06
JP2002502823A (ja) 2002-01-29
CA2319448A1 (en) 1999-08-12
WO1999039727A1 (en) 1999-08-12
EP1053006A4 (de) 2002-09-25
EP1058555A1 (de) 2000-12-13
EP1058555A4 (de) 2001-02-28
EP1053006A1 (de) 2000-11-22
AU2588099A (en) 1999-08-23
IL137614A0 (en) 2001-07-24
IL137361A0 (en) 2001-07-24
EP1058555B1 (de) 2004-04-28
US6280957B1 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
DE69916807D1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
ES2195664T3 (es) Uso de fumaratos de dialquilo.
ES2194106T3 (es) .ompuestos de imidazol
TR200103216T2 (tr) Pirimidinon bileşimleri
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ES2300276T3 (es) P40 de interleuquina-12 de mamifero e interleuquina b30. sus combinaciones. anticuerpos. usos en composiciones farmaceuticas.
ATE233735T1 (de) Neue phenanthridine
DK0733109T3 (da) BMP-12, BMP-13 og seneinducerende præparater dermed
PT935465E (pt) Compostos novos de imidazole substituido
NZ527076A (en) Graft rejection inhibitors used in combination with immunosuppressants
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
FR2749022B1 (fr) Cellules aviaires immortelles
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
NO20031860D0 (no) Kahalaolid F
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
IS4915A (is) Samsetningar sem innihalda VX478, Zídóvúdín, FTC og/eða 3TC til að nota við meðhöndlunina á HIV
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
HUP0101393A1 (hu) Redukáló körülményekre érzékeny transzfektáló kompozíciók, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE221388T1 (de) Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten
DE69940533D1 (de) Leistungsverstärker mit sanfter Umschaltung und Mehrpegel-Schaltzellen
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof
DE60330223D1 (de)
YU180791A (sh) Injekcioni proizvod za sitni pesak i druge porozne materijale

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties